Expression of podoplanin in epithelial ovarian carcinomas and its potential as a marker for clear cell adenocarcinoma

International Journal of Gynecological Pathology

Volumn 29, Issue 5, 2010, Pages 405-410

  Oe, Shuko ^a   Hasegawa, Kiyoshi ^a   Nagase, Sayaka ^a   Kato, Rina ^a   Torii, Yutaka ^a   Udagawa, Yasuhiro ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Clear cell adenocarcinoma; Epithelial ovarian carcinoma; Podoplanin

Indexed keywords

PODOPLANIN;

ADENOCARCINOMA; ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA, CLEAR CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MEMBRANE GLYCOPROTEINS; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77956224676     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/PGP.0b013e3181d3261e     Document Type: Article

References (27)

1. Breiteneder-Geleff S, Soleiman A, Kowalski H, et al. Angio-sarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 1999;154:385-394
2. Breiteneder-Geleff S, Matui K, Soleiman A, et al. Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol 1997; 151:1141-1152
3. Schacht V, Ramirez MI, Hong YK, et al. T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J 2003;22:3546-3556
4. Dobbs LG, Williams MC, Gonzalez R. Monoclonal antibodies specific to apical surfaces of rat alveolar type 1 cells bind to surfaces of cultured, but not fleshly isolated, type 2 cells. Biochim Biophys Acta 1988;970:146-156
5. Schacht V, Johnson LA, Jackson DJ, et al. Up-regulation of the lymphatic Marker Podoplanin, a mucin-type transmem-brane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 2005;166:913-921
6. Kimura N, Kimura I. Podoplanin as a marker for mesothe-lioma. Pathol Int 2005;55:83-86
7. Kato Y, Sasagawa I, Kaneko M, et al. Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene 2004;23: 8552-8556
8. Straume O, Jackson DG, Akslen LA. Independent prognostic impact of lymphatic vessel density and presence of low-grade lymphangiogenesis in cutaneous melanoma. Clin Cancer Res 2003;9:250-256
9. Schoppmann SF, Bayer G, Aumayr K, et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 2004;240:306-312
10. Schmid K, Briner P, Gravenhorst V, et al. Prognostic value of lymphatic and blood vessel invasion in neuroendocrine tumors of the lung. Am J Surg Pathol 2005;29:324-328
11. Kyzas PA, Geleff S, Batistatou A, et al. Evidence for lymphangiogenesis and its prognostic implications in head and neck squamous cell carcinoma. J Pathol 2005;206:170-177
12. Sipos B, Klapper W, Kruse ML, et al. Expression of lympha-ngiogenic factors and evidence of intratumoral lymphangio-genesis in pancreatic endocrine tumors. Am J Pathol 2004;165: 1187-1197
13. Carroll PA, Brazeau E, Lagunoff M. Kaposi's sarcoma-associated herpesvirus infection of blood endothelial cells induces lymphatic differentiation. Virology 2004;328:7-18.
14. Dumoff KL, Chu CS, Harris EE, et al. Low podoplanin expression in pretreatment biopsy material predicts poor prognosis in advanced-stage squamous cell carcinoma of the uterine cervix treate by primary radiation. Modern Pathol 2006;19:708-716
15. Detre S, Jotti GS, Dowsett M. A "quickscore" method for immunohistochemical semi-quantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995;48:876-878
16. Tsuchiya A, Sakamoto M, Yasuda J, et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 2003;163:2503-2512
17. Tammela J, Geisler JP, Eskew PN Jr, et al. Clear cell carcinoma of the ovary: poor prognosis compared to serous carcinoma. Eur J Gynecol Oncol 1998;19:438-440
18. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary. Cancer 2000; 88:2584-2589
19. Takano M, Kikuchi Y, Yagashi N, et al. Clear cell carcinoma of the ovary: a retrospective multicenter experience of 254 patients with complete surgical staging. Br J Cancer 2006;94:1369-1374
20. Wicki A, Lehembre F, Wick N, et al. Tumor invasion in the absence of epitherial-mesenchymal transition: podoplanin-mediated remodeling of actin cytoskeleton. Cancer Cell 2006; 9:261-272
21. Moustakas A, Heldin CH. Signaling networks guiding epithelial-mesenchymal transition during embryogenesis and cancer progression. Cancer Sci 2007;98:1512-1520
22. Wicki A, Christofori G. The potential role of podoplanin in tumour invasion. Br J Cancer 2007;96:1-5.
23. Williams MC, Cao Y, Hinds A, et al. T1a protein is developmentally regulated and expressed by alveolar type I cells, choroid plexus, and ciliary epithelia of adult rats. Am J Resp Cell Mol 1996;14:577-585
24. Zimmer G, Oeffner F, Messling V, et al. Cloning and characterization of gp36, a human mucin-type glycoprotein preferentially expressed in vascular endothelium. Biochem J 1999;341:277-284
25. Kato Y, Fujita N, Kunita A, et al. Molecular identification of Aggrus/T1a as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem 2003;278:51599-51605
26. Kaneko M, Kato Y, Kunita A, et al. Functional sialylated o-glycan to platelet aggregation on aggrus (T1a/Podoplanin) molecules expressed in Chinese hamster ovary cells. J Biol Chem 2004;279:38838-38843
27. Matsuura Y, Robertson G, Marsden DE, et al. Thrombolic complications in patients with clear cell carcinoma of the ovary. Gynecol Oncol 2007;104:406-410